drugset / Trial / NCT04416633
Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC
NaSingle-groupOpen-labelTreatment
Summary
A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC)
Timeline
- Start
- 2021-11-30
- Primary completion
- 2023-10-27
- Completion
- 2023-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 120 mg | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 500 mg | Intravenous |